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argument for the use of mixed components in primary THA 
could be the need for a dual mobility cup in case of high risk 
of instability. Other arguments could be altered anatomy (e.g., 
developmental dysplasia of the hip), patient characteristics 
(e.g., frail elderly patients requiring cemented stems), and 
high-risk patients (e.g., prior lumbar spine fusion with irradi-
ated pelvis). In revision arthroplasty, combining components 
from different manufacturers could be considered in order to 
prevent additional patient morbidity (e.g., leaving a well-fixed 
stem from another company in situ during a cup revision) 
(Mueller et al. 2018), or to optimize component placement 
performed by surgeons with extensive clinical experience. 
This is all in the best interest of the patient. 
Hard-on-soft mixing and matching across the femo-
ral head and acetabular component (mobile bearings) have 
demonstrated excellent results for several combinations. For 
example, data from the National Joint Registry of England 
and Wales (NJR) showed that cemented stems with mixed 
polyethylene cups were associated with a lower risk for revi-
sion compared with their manufacturer-matched equivalents 
(Tucker et al. 2015).
For fixed combinations, different taper sizes used by the 
various manufacturers have made it difficult for surgeons to 
combine the stem and head junction properly, as the stems 
and head can vary in shape, metallurgy, roughness, inclina-
tion, and angle (Werner et al. 2015). Mixed components over 
the trunnion–taper junction in THAs with large head and 
hard-on-hard bearings may result in wear of the femoral head–
neck interface (trunnionosis), which has been reported as an 
increasingly prevalent cause of failure (Mistry et al. 2016). In 
THAs with ceramic heads, a mismatch can result in a frac-
tured femoral head component. 
About 300 different hip prostheses promoted by a multitude of 
distributors are available on the European market. Most total 
hip arthroplasties (THAs) are assembled from components 
produced by the same manufacturer (non-mixed THAs), yet 
certain situations require a combination of components from 
different manufacturers within a single hip prosthesis (mixed 
THAs). Despite it being against manufacturers’ guidelines 
(Smith & Nephew 2013, Link 2018), orthopedic surgeons 
who do this are encouraged by clinical results that are compa-
rable to and sometimes even superior to those obtained with-
out mixed components (Tucker et al. 2015, Peters et al. 2016, 
Taylor et al. 2018). This mixing and matching is common 
clinical practice. The question does remain as to whether it is 
allowable by law. In this annotation paper we assess the legal-
ity of mixed THAs based on European law.
Mix and match: clinical perspective 
Mixed prostheses are defined as THAs (stem, head, and cup) 
comprising components made by different manufactures. With 
a reported prevalence of 11%, 24%, and 15% in the Nether-
lands, New Zealand, and England and Wales, respectively, 
mixing and matching is common clinical practice (Tucker et 
al. 2015, Peters et al. 2016, Taylor et al. 2018). Based on these 
national joint registry studies, it was demonstrated that mixed 
THAs yield at least comparable and for certain combinations 
even better outcomes than THAs with components from the 
same manufacturer (Tucker et al. 2015, Peters et al. 2016, 
Taylor et al. 2018). 
The concept of mixed THA refers to both fixed (trunnion/
taper) and mobile (head/cup) combinations as well as hard-on-
soft and hard-on-hard bearings. A distinction should addition-
ally be made between primary and revision procedures. An 
2 Acta Orthopaedica 2020; 91 (x): x–x
Legal implications 
The use of mixed components gives rise to legal implications 
from public and private law. One aspect of public law is that 
orthopedic implants have to be approved and marked Confor-
mité Européene by an appropriate body before being allowed 
on the European market. This approval is given if the product 
meets the requirements of the Medical Devices Directive or 
its successor, the Medical Device Regulation, e.g., that the 
implant does not entail a safety risk (Directive 93/42/EEC 
1993, Regulation (EU) 2017/745 2017). If a product is altered 
or a new product is designed by using several components that 
are not tested together, this approval might no longer be valid. 
Implications may derive from private law too. The unauthor-
ized mixing of components can give rise to a risk of liability 
toward patients, as liability could be imposed for (1) produc-
ing a defective product or (2) medical negligence. 
Product liability 
Orthopedic surgeons who combine components from differ-
ent manufacturers that are not designed, tested, or meant to 
be combined in compliance with the producers of the compo-
nents bear a liability risk toward the patient. This risk derives 
from the European Product Liability Directive (85/374/EEC), 
which states that the producer of a product is liable for dam-
ages suffered by a patient if this product appears to be defec-
tive. This Directive is transposed into national law of all 
member states of the European Union and the European Free 
Trade Association. A healthcare provider who mixes compo-
nents, such as a femoral head and stem from manufacturer A 
with a cup from manufacturer B, into a THA could qualify as 
a “manufacturer of a finished product” to whom the liability 
regime of the Directive applies (Gabrielczyk 2017). 
Defective product
In order for a producer (manufacturer or orthopedic surgeon) 
to be liable, the product has to be defective. This means that 
the product does not provide the safety that an individual is 
entitled to expect (article 6 of the Directive). Relevant in this 
respect is a recent English ruling that metal-on-metal (MoM) 
prostheses were not defective in terms of the entitled expecta-
tion of safety of such prostheses in 2002 (Colin Gee and others 
v. Depuy International Limited 2018). To determine whether 
a product provides the safety a person is entitled to expect, 
relevant circumstances are: the presentation of the product, the 
use to which the product could reasonably be expected to be 
put, and the time when the product was put into circulation. 
With regard to the latter: the defectiveness will be determined 
based on the state of knowledge and safety standards at the 
time it was put into circulation. The fact that a better prod-
uct was subsequently put into circulation will not lead to the 
conclusion that the product in question must be considered 
defective. For orthopedic surgeons, this means that the state of 
knowledge at the time of insertion of the prothesis is impor-
tant. In this respect it is relevant, for instance, that it was dem-
onstrated in 2015 that the use of heads and stems from differ-
ent manufacturers in mixed THAs leads to increased revision 
rates (Tucker et al. 2015).
Under certain circumstances, the producer can avoid the 
liability described above. Article 7 from the Directive sums up 
several defenses. For example, the producer will not be liable 
if it was impossible to know the risk that led to the defect 
because of a lack of knowledge. This refers to the objective 
scientific and technical knowledge available and accessible at 
that time, “including the most advanced level of such knowl-
edge” (Commission of the European Communities v. United 
Kingdom of Great Britain and Northern Ireland 1997). As 
regards THAs the defense will most likely be unsuccessful 
if, at the time the THA was used by the surgeon, there was 
published scientific research available pointing out the risks of 
mixing components and materials. 
Medical negligence
Mixing of components could also result in liability of the 
healthcare provider if it qualifies as negligence. Liability for 
medical negligence is not regulated at the EU level, so regimes 
will vary per country. Generally, liability will require negli-
gent behavior from the healthcare provider, meaning that he 
or she must have breached a standard of care (Cass 1936, HR 
1990, BGH 1994, Bolam v. Friern HMC 2015). As opposed 
to the previous regime of strict liability of the producer, medi-
cal negligence generally requires that the healthcare provider 
commits a fault. Mixing of components might be considered 
negligent when it is unauthorized and discouraged by the 
manufacturer, untested by the orthopedic surgeon and unap-
proved according to public law—all the more in a primary 
situation, when reasonable alternatives are available and when 
medical publications have shown clinical risks. Whether or 
not the healthcare provider has acted negligently will be influ-
enced by the communication of these risks to the patient and 
the receipt of the patient’s consent. And yet this might not be 
decisive due to the differences in knowledge and expertise 
between healthcare providers and patients. So, when mixing 
is a reasonable option, it is important to inform the patient 
about the use of mixed components, the benefits and potential 
risks, and reasonable alternatives, in order to gain the patient’s 
consent.
A search of case law in the United Kingdom (UK), Germany, 
and the Netherlands revealed that until now no orthopedic sur-
geon has ever been held responsible as the manufacturer of a 
finished product of mixed components. In the past one trial in 
the UK has been started but this has not resulted in a ruling 
in which the orthopedic surgeon was held responsible as the 
manufacturer of a finished product of mixed components.
Conclusion
Mixing and matching in total hip arthroplasty is common 
practice worldwide. It is generally done in the interest of the 
patient, aiming to optimize the outcome of the treatment. We 
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assessed the rules for mixed THAs based on European law, 
to create awareness of the legality. Despite evident medical 
benefits and similar or even superior revision rates compared 
with non-mixed THAs (Tucker et al. 2015, Peters et al. 2016, 
Taylor et al. 2018), from a legal perspective it is advisable to 
avoid mixing when reasonable alternatives are available, espe-
cially in primary arthroplasty. The unauthorized mixing of 
components can create a liability risk based on European and 
national law. An orthopedic surgeon who mixes components 
from different manufactures could qualify as a “manufacturer 
of a finished product” and may be held liable without fault 
if the product appears to be defective. However, to date, no 
orthopedic surgeon has been held legally responsible or ended 
up in a lawsuit for the use of mixed components, based on case 
law review in the United Kingdom, Germany, and the Neth-
erlands. Although no search was done of case laws in other 
European countries we presume that the situation in these 
countries can be considered representative of the situation in 
Europe as a whole. 
If a situation does require the use of mixed components, 
surgeons are best advised to (1) avoid mixing across the fixed 
articulation (i.e., use a head from the same manufacturer as the 
stem), (2) appropriately match sizes across the mobile articu-
lation in hard-on-soft THAs (Tucker et al. 2015, Taylor et al. 
2018), and (3) avoid mixing in hard-on-hard bearings. Sur-
geons are likewise advised to gain knowledge on the results of 
specific component combinations (e.g., based on arthroplasty 
registry results) and to explain the choices to the patient in 
order to receive his/her consent. 
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